Neuropharmacology

Switching the Disease Off: Effects of Spatial and Temporal Inactivation of Mutant Huntingtin in Huntington’s Disease - August, 2013

QPS Austria is collaborating with the University of Tuebingen, Germany, in the EU-supported Marie-Curie project: “Switching the disease off: effects of spatial and temporal inactivation of mutant huntingtin in Huntington’s Disease.” The goal of this Industry-Academia Partnerships and Pathways project is to investigate the role of mutant huntingtin (mhtt) in the striatum and hypothalamus. Utilizing lentiviral delivery of CRE recombinase in the unique BACHD rat, down regulation of mhtt in these brain regions will be examined at various disease stages. For the first time, this method will allow us to determine which mhtt-containing brain region is causing which Huntington’s Disease symptom. Translation of these results to the human disease will allow the development of more specific treatments for Huntington’s Disease.

If you are interested in testing your drug candidate(s) in a novel BACHD transgenic rat exhibiting the characteristic neuropathological features of Huntington disease, please click on the link below:

back
top
20 years in pharma R&D navigation